Currently, Xeris Biopharma Holdings Inc [XERS] is trading at $2.91, up 4.30%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The XERS shares have gain 3.93% over the last week, with a monthly amount glided 12.36%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Xeris Biopharma Holdings Inc [NASDAQ: XERS] stock has seen the most recent analyst activity on March 28, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $5. Previously, Craig Hallum started tracking the stock with Buy rating on August 28, 2023, and set its price target to $4.50. On October 21, 2022, Jefferies initiated with a Buy rating and assigned a price target of $4 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $6.50 on April 28, 2022. SVB Leerink initiated its recommendation with a Outperform and recommended $6 as its price target on November 17, 2021. H.C. Wainwright started tracking with a Buy rating for this stock on October 29, 2021, and assigned it a price target of $4.
This stock has fluctuated between a low of $1.46 and a high of $3.26 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $4.75 within the next 12 months. Xeris Biopharma Holdings Inc [NASDAQ: XERS] shares were valued at $2.91 at the most recent close of the market. An investor can expect a potential return of 63.23% based on the average XERS price forecast.
Analyzing the XERS fundamentals
Trailing Twelve Months sales for Xeris Biopharma Holdings Inc [NASDAQ:XERS] were 181.41M which represents 26.46% growth. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -0.2%, Pretax Profit Margin comes in at -0.33%, and Net Profit Margin reading is -0.33%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is 7.59 and Total Capital is -0.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -12.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.80 points at the first support level, and at 2.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.97, and for the 2nd resistance point, it is at 3.03.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Xeris Biopharma Holdings Inc [NASDAQ:XERS] is 2.26. As well, the Quick Ratio is 1.69, while the Cash Ratio is 0.76. Considering the valuation of this stock, the price to sales ratio is 2.39.
Transactions by insiders
Recent insider trading involved Schmid John P., Director, that happened on Aug 12 ’24 when 4515.0 shares were purchased. Director, Schmid John P. completed a deal on Aug 09 ’24 to buy 4285.0 shares. Meanwhile, Director Schmid John P. bought 5400.0 shares on May 10 ’24.
